Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
about
Epilepsy during pregnancy: focus on management strategiesUse of Therapeutic Drug Monitoring, Electronic Health Record Data, and Pharmacokinetic Modeling to Determine the Therapeutic Index of Phenytoin and Lamotrigine.Does the placebo effect modulate drug bioavailability? Randomized cross-over studies of three drugs.Generic Substitution of AEDs: Is it Time to Put This Issue to Rest?Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.Safety of switching from brand-name to generic levetiracetam in patients with epilepsy.Switching generic antiepileptic drug manufacturer not linked to seizures: A case-crossover study.Assessing bioequivalence of generic modified-release antiepileptic drugs.Brand Spanking II: Attack of the Clones (or, The Phantom Menace).AES Position Statement on Generic Substitution of Antiepileptic Drugs.Generic Modified-Release Antiepileptic Drugs: No Difference Within Formulations, but Important Differences Across FormulationsGeneric-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs.Generic Versions of Narrow Therapeutic Index Drugs: A National Survey of Pharmacists' Substitution Beliefs and Practices.Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).Risk-Based Bioequivalence Recommendations for Antiepileptic Drugs.Safety of Overnight Switch from Brand-Name to Generic Levetiracetam.Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study.Advocacy for children with epilepsy: Leveraging the WHA resolution. Advocacy Task Force, Commission of Pediatrics, International League Against Epilepsy.
P2860
Q28080299-5C43B4E2-0398-468D-AC06-1EE5718F1386Q31138033-D5B4623D-6197-4939-96DA-8624783FADFEQ33721952-9985562D-3AA2-41E3-A098-59422E49737AQ38350218-01808D4A-3CA9-4EBD-AD35-D7EE1FB473F6Q38374905-2AE7352C-4A46-4974-8E9F-D455EE6FA4EAQ38621374-3B7FB25B-77AB-48D4-8CB2-3078B9E3A10EQ39340691-382A3310-B0AE-4590-BF3D-20B86F45FF04Q39887948-A58DD13D-AE5E-4DA4-B8E9-E2B50FC4318FQ41596638-3C5B7CF1-E6B0-473C-A855-1F78C53A3E48Q42060862-84B67098-B269-4B86-9890-C88A3793DEB8Q42317851-5C3D2336-C382-4E9F-BCC6-353FFF459A10Q47114415-42BD712C-C502-46B1-921B-2AE4A9BC1C16Q47699757-2549EABA-3853-4A86-A599-F20F4CA90AC3Q47847824-FAE7E53F-3938-4A31-A4DF-A0FE41B563A0Q50001792-49750B7C-2B50-477A-B705-BE7968AB20E1Q52664925-D022B533-4A4C-4B8C-B6F5-C609152A52C6Q55005295-25349FD3-07AD-4402-80F8-DE422E252DDDQ55277254-26DFA0A5-C25C-44C0-94A8-0BB0D9949AE4
P2860
Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Generic lamotrigine versus bra ...... e FDA bioequivalence standard.
@en
type
label
Generic lamotrigine versus bra ...... e FDA bioequivalence standard.
@en
prefLabel
Generic lamotrigine versus bra ...... e FDA bioequivalence standard.
@en
P2093
P2860
P356
P1433
P1476
Generic lamotrigine versus bra ...... e FDA bioequivalence standard.
@en
P2093
Allan Krumholz
Jace W Jones
James E Polli
Jessica Wong
Maureen A Kane
Robert Lionberger
Robert Temple
Tricia Y Ting
Wenlei Jiang
P2860
P304
P356
10.1111/EPI.13095
P577
2015-07-23T00:00:00Z